Dual‐Phase C‐11 PiB PET Images for Detecting Tau Pathology in Cerebral Amyloid Angiopathy
ABSTRACT Background Cerebral amyloid angiopathy (CAA) is a major cause of lobar intracerebral hemorrhage and cognitive dysfunction in the elderly, and frequently coexists with Alzheimer's disease and tau pathology. Dual‐phase 11C‐PiB PET detects amyloid deposition and cerebral perfusion changes...
Saved in:
Published in | Annals of clinical and translational neurology Vol. 12; no. 5; pp. 905 - 914 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
United States
John Wiley & Sons, Inc
01.05.2025
John Wiley and Sons Inc Wiley |
Subjects | |
Online Access | Get full text |
ISSN | 2328-9503 2328-9503 |
DOI | 10.1002/acn3.70021 |
Cover
Loading…
Summary: | ABSTRACT
Background
Cerebral amyloid angiopathy (CAA) is a major cause of lobar intracerebral hemorrhage and cognitive dysfunction in the elderly, and frequently coexists with Alzheimer's disease and tau pathology. Dual‐phase 11C‐PiB PET detects amyloid deposition and cerebral perfusion changes and may have diagnostic value for identifying tau in CAA.
Methods
We prospectively enrolled patients with probable CAA for dynamic PiB and AV1451 scans. We compared early‐phase (0–6 min after tracer injection) and late‐phase (40–70 min) PiB PET between the tau(+) and tau(−) groups (based on AV1451 PET) and investigated their diagnostic values for detecting tau.
Results
CAA/tau(+) had lower early‐phase temporal PiB uptake than CAA/tau(−) (p = 0.014) and higher late‐phase uptake in the whole cortex and temporal and parietal lobes (all p < 0.05). Early‐phase temporal PiB SUVR correlated with tau burden (r = −0.34, p = 0.038). Using Youden's cut‐off, early‐phase and late‐phase PET had sensitivities of 55% and 80% and specificities of 85% and 65% for detecting tau, respectively. Combining early‐ and late‐phase scans provided a rule‐out sensitivity of 90% and rule‐in specificity of 100% for tau pathology in CAA.
Conclusions
Dual‐phase 11C‐PiB PET represents a reliable approach for assessing tau and could potentially identify CAA patients for tau biomarker testing. |
---|---|
Bibliography: | Funding This work was supported by grants from Taiwan National Science and Technology Council (Tsai HH, 113‐2628‐B‐002‐013‐MY3) and National Taiwan University Hospital (Liu CJ, 113‐N0075 and 113‐X0018). Chia‐Ju Liu and Hsin‐Hsi Tsai contributed equally to this work. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Funding: This work was supported by grants from Taiwan National Science and Technology Council (Tsai HH, 113‐2628‐B‐002‐013‐MY3) and National Taiwan University Hospital (Liu CJ, 113‐N0075 and 113‐X0018). |
ISSN: | 2328-9503 2328-9503 |
DOI: | 10.1002/acn3.70021 |